The interaction of metabolic factors with HCV infection: Does it matter?

https://doi.org/10.1016/S0168-8278(12)60007-5Get rights and content

Summary

Given the pandemic spread of the hepatitis C virus (HCV) infection and the metabolic syndrome (MS), the burden of their interaction is a major public health issue, bound to increase in the near term. A better appreciation of the clinical consequences of the relationship between HCV and MS is needed, not only due to their potential synergism on liver disease severity, but also because of the multifaceted interactions between HCV and glucose and lipid metabolism. HCV infection per se does not carry an increased risk of MS, but is able to perturb glucose homeostasis through several direct and indirect mechanisms, leading to both hepatic and extrahepatic insulin resistance. This translates into accelerated liver disease progression (including the development of hepatocellular carcinoma), reduced response to antivirals and, in susceptible individuals, increased risk of developing full-blown type 2 diabetes. HCV may also cause hepatic steatosis, especially in patients infected with genotype 3, although the clinical impact of viral steatosis is debated. Possibly as a result of HCV-induced insulin resistance, and despite a paradoxically favourable lipid profile, the cardiovascular risk is moderately increased in chronic hepatitis C. In addition, the interaction with the MS further increases the risks of cirrhosis, hepatocellular carcinoma, diabetes, and cardiovascular events. Thus, targeted lifestyle and pharmacological measures are urgently warranted in chronic hepatitis C with metabolic alterations.

References (121)

  • L Rui et al.

    SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2

    J Biol Chem

    (2002)
  • JF Tanti et al.

    Cellular mechanisms of insulin resistance: role of stressregulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation

    Curr Opin Pharmacol

    (2009)
  • S Aytug et al.

    Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes

    Hepatology

    (2003)
  • T Kawaguchi et al.

    Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3

    Am J Pathol

    (2004)
  • C Bernsmeier et al.

    Virus-induced over-expression of protein phosphatase 2A inhibits insulin signaling in chronic hepatitis C

    J Hepatol

    (2008)
  • C García-Monzón et al.

    Hepatic insulin resistance is associated with increased apoptosis and fibrogenesis in nonalcoholic steatohepatitis and chronic hepatitis C

    J Hepatol

    (2011)
  • B Chandrasekar et al.

    Adiponectin blocks interleukin-18-mediated endothelial cell death via APPL1-dependent AMP-activated protein kinase (AMPK) activation and IKK/NF-kappaB/PTEN suppression

    J Biol Chem

    (2008)
  • B Emanuelli et al.

    SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice

    J Biol Chem

    (2001)
  • H Zylberberg et al.

    Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity

    J Hepatol

    (1999)
  • H Knobler et al.

    Tumor necrosis factor-alpha-induced insulin resistance may mediate the hepatitis C virus-diabetes association

    Am J Gastroenterol

    (2003)
  • P Tarugi et al.

    Molecular diagnosis of hypobetalipoproteinemia: an ENID review

    Atherosclerosis

    (2007)
  • M Shaheen et al.

    Hepatitis C, metabolic syndrome, and inflammatory markers: results from the Third National Health and Nutrition Examination Survey [NHANES lll]

    Diabetes Res Clin Pract

    (2007)
  • AJ Czaja et al.

    Host- and disease-specific factors affecting steatosis in chronic hepatitis C

    J Hepatol

    (1998)
  • L Rubbia-Brandt et al.

    Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3

    J Hepatol

    (2000)
  • LE Adinolfi et al.

    Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

    Hepatology

    (2001)
  • D Kumar et al.

    Hepatitis C virus genotype 3 is cytopathic to hepatocytes. Genotype-specific reversal of hepatic steatosis after sustained response to antiviral therapy

    Hepatology

    (2002)
  • T Poynard et al.

    Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C

    Hepatology

    (2003)
  • K Abid et al.

    An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation

    J Hepatol

    (2005)
  • H Lerat et al.

    Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus

    Gastroenterology

    (2002)
  • S McPherson et al.

    Investigation of the role of SREBP-1c in the pathogenesis of HCV-related steatosis

    J Hepatol

    (2008)
  • T Tsutsumi et al.

    Interaction of hepatitis C virus core protein with retinoid X receptor alpha modulates its transcriptional activity

    Hepatology

    (2002)
  • C Jackel-Cram et al.

    Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype-1b core

    J Hepatol

    (2007)
  • H Lerat et al.

    Hepatitis C virus proteins induce lipogenesis and defective triglyceride secretion in transgenic mice

    J Biol Chem

    (2009)
  • L Serfaty et al.

    Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C

    J Hepatol

    (2001)
  • H Hofer et al.

    Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a

    Am J Gastroenterol

    (2002)
  • S Mirandola et al.

    Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis

    Gastroenterology

    (2006)
  • S Dharancy et al.

    Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection

    Gastroenterology

    (2005)
  • T Cai et al.

    Viral genotype-specific effect of PNPLA3, PPARG, IL28B and MTTP on hepatitis C virus-associated steatosis

    J Hepatol

    (2011)
  • H Völzke et al.

    Hepatitis B and C virus infection and the risk of atherosclerosis in a general population

    Atherosclerosis

    (2004)
  • G Targher et al.

    Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C

    J Hepatol

    (2007)
  • M Boddi et al.

    HCV infection facilitates asymptomatic carotid atherosclerosis: preliminary report of HCV RNA localization in human carotid plaques

    Dig Liver Dis

    (2007)
  • CL Chen et al.

    Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan

    Gastroenterology

    (2008)
  • G Nkontchou et al.

    Insulin resistance, serum leptin, and adiponectin levels and outcomes of viral hepatitis C cirrhosis

    J Hepatol

    (2010)
  • P Zimmet et al.

    Global and societal implications of the diabetes epidemic

    Nature

    (2001)
  • GL Davis et al.

    Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression

    Gastroenterology

    (2010)
  • V Kaddai et al.

    Current understanding of insulin resistance in hepatitis C

    Expert Rev Gastroenterol Hepatol

    (2011)
  • F Negro

    Abnormalities of lipid metabolism in hepatitis C virus infection

    Gut

    (2010)
  • Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults

    Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

    JAMA

    (2001)
  • KG Alberti et al.

    Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity

    Circulation

    (2009)
  • SH Mehta et al.

    Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States

    Ann Intern Med

    (2000)
  • Cited by (159)

    • Fatty Liver Disease

      2023, MacSween's Pathology of the Liver, Eighth Edition
    • Extrahepatic Manifestations of Chronic Viral C Hepatitis

      2020, Gastroenterology Clinics of North America
    View all citing articles on Scopus
    View full text